{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-25-000011","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.669682+00:00","generated_at":"2026-05-17T04:04:23.475215+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"medium","headline":"Avalo Therapeutics posts updated investor presentation; no material new data disclosed","bullets":["Presentation dated October 2025 describes pipeline of novel IL-1β therapies.","No new clinical data, financial results, or guidance changes included in update.","Presentation used for routine investor meetings; no material events announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-25-000011","json":"https://secwatch.observer/filing/0001534120-25-000011.json","markdown":"https://secwatch.observer/filing/0001534120-25-000011.md","text":"https://secwatch.observer/filing/0001534120-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000011/0001534120-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000011/avtx-20251010.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:04:23.475215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}